Skip to main content
. 2021 Apr 22;6(8):e145936. doi: 10.1172/jci.insight.145936

Figure 11. Attenuation of sphingolipid accumulation in AAV-SPL–treated Sgpl1-KO mice.

Figure 11

S1P, dihydrosphingosine-1-phosphate (DHS1P), sphingosine, and dihydrosphingosine (DHS) in the (A) liver and (B) plasma of WT (n = 9), KO (n = 7), and AAV-SPL–treated KO (AAV, n = 4) mice. For liver S1P, liver DHS1P, and plasma sphingosine, Mann-Whitney U with Bonferroni’s correction was applied. For liver sphingosine, liver DHS, plasma S1P, and plasma DHS1P, unpaired t test with Bonferroni’s correction was applied, and for liver DHS and plasma DHS1P, Welch’s correction was additionally applied. For plasma DHS, Kruskal-Wallis was applied. For liver S1P: KO vs. WT/HET, P < 0.004; AAV vs. WT/HET, P = 0.0058; AAV vs. KO, P = 0.012. For liver sphingosine: KO vs. WT/HET, P < 0.0002; AAV vs. WT/HET, P < 0.0002; AAV vs. KO, P = 0.0016. For liver DHS1P: KO vs. WT/HET, P = 0.0004; AAV vs. WT/HET, P = 0.0112; AAV vs. KO, P = 0.0122. For liver DHS: KO vs. WT/HET, P = 0.0006; AAV vs. WT/HET, P = 0.0062; AAV vs. KO, P = 0.049. For plasma S1P: KO vs. WT/HET, P = 0.0002; AAV vs. WT/HET, P = 0.0002; AAV vs. KO, P = 0.014. For plasma sphingosine: KO vs. WT/HET, P < 0.0002; AAV vs. WT/HET, P < 0.0018; AAV vs. KO, P = 0.033. For plasma DHS1P: KO vs. WT/HET, P = 0.001; AAV vs. WT/HET, P < 0.0002; AAV vs. KO, P = 0.0048. For plasma DHS: there were NSDs in any of the groups.